Roy Wouters - Managing Director in the EMEA Healthcare Investment Banking team at Bank of America & Sumit Mukherjee - Head of Healthcare ECM, Global Capital Markets based in New York.

Roy is based in London and has responsibility for origination and execution of strategic advisory and corporate finance assignments in life sciences, with a broad range of clients spanning from large pharmaceutical companies through to emerging biotechs. 

In recent years, Roy has helped numerous European biotechs access U.S. investors via the capital markets. His most recent deals include Achilles Therapeutics’ $175m US IPO (2021), BioNTech’s $512m follow-on offering and $250m private placement (2020) and $158m US IPO (2019), Orphazyme’s $84m Global Offering and US IPO (2020) and Hookipa’s $84m IPO (2019). Additionally he advised Bayer in the $8bn sale of their Animal Health business to Elanco (2020), Novartis in their $9.7bn acquisition of The Medicines Co. (2020) and $31bn 100% spin-off of Alcon and listing on SIX and NYSE (2019) as well as UCB in their $2.1bn acquisition of Ra Pharma (2019).

Sumit partners with BofA’s Global Corporate and Investment Banking (GCIB) team to advise clients on all aspects of their equity capital needs, including raising private or public capital. His primary responsibilities include managing the IPO process from pitch through pricing, helping public companies raise capital to fund growth or manage their balance sheet as well as help strategic or sponsor/venture clients monetize positions they own within healthcare.